Thursday, August 25, 2011

Powerful fluorescence tool lights the way to new insights into RNA of living cells

ScienceDaily (July 30, 2011) — The ability to tag proteins with a green fluorescent light to watch how they behave inside cells so revolutionized the understanding of protein biology that it earned the scientific teams who developed the technique Nobel Prizes in 2008. Now, researchers at Weill Cornell Medical College have developed a similar fluorescent tool that can track the mysterious workings of the various forms of cellular RNA.See Also:Plants & AnimalsBiologyCell BiologyBiotechnologyMatter & EnergyBiochemistryOrganic ChemistryTechnologyReferenceRNATrait (biology)OrganelleMolecular biology

In the July 29 issue of Science, the Weill Cornell investigators report how they developed an RNA mimic of green fluorescent protein (GFP) -- which they dubbed Spinach -- and describe how it will help unlock the secrets of the complex ways that RNA sustains human life as well as contributes to disease.

"These fluorescent RNAs offer us a tool that will be critical for understanding the diverse roles that RNA plays in human biology," says the study's senior author, Dr. Samie Jaffrey, an associate professor of pharmacology at Weill Cornell Medical College.

In recent years, the many roles played by RNA have become clearer. "Scientists used to think that RNA's function was limited to making proteins and that these proteins alone dictated everything that happened in cells," he says. "But now we are understanding that cells contain many different forms of RNA -- and some RNAs influence cell signaling and gene expression without ever being used for synthesizing proteins."

The list of known types of RNA has grown rapidly over the past several years -- from messenger RNA that codes for proteins, to diverse "non-coding" RNAs that affect translation and gene expression, and in some cases bind to proteins and regulate their function -- yet little is known about how these RNAs work, the researchers say.

The study's first author, Dr. Jeremy Paige, who conducted the research as a graduate student in pharmacology at Weill Cornell Medical College, adds that the new technology may provide insights into the development of common disorders. "More and more diseases are being linked to misregulation of RNA, but without being able to see the RNA, we can't understand how these processes lead to disease.

"We hope our RNA mimics of GFP open up the road to discovery," he says.

The RNAs developed by the Jaffrey group function like GFP, a natural protein expressed in jellyfish that exhibits a green fluorescence. GFP has enabled scientists to watch how proteins move in cells, providing powerful new insights into their roles in cell function. The DNA that encodes GFP is placed next to a gene that encodes for a protein, resulting in the expression of a protein fused to GFP, which can be observed by specialized forms of microscopy.

To make an RNA that functions like GFP, the Weill Cornell investigators took advantage of the ability of RNA to fold into complex three-dimensional shapes. Their goal was to create two new entities: a synthetic RNA sequence that would adopt a specific shape, and a small molecule that would bind to the new RNA and begin to fluoresce. "These were two huge challenges," says Dr. Jaffrey. "One challenge was to come up with an RNA sequence that could 'switch on' a small molecule. The other big hurdle was to find a small molecule that would fluoresce only when we wanted it to and would not be toxic to cells."

They tried a number of molecules, most of which stuck to oily lipids in the cell membrane and started fluorescing, or they would kill the cell. Finally, the team realized that GFP itself had a molecule, a fluorophore, within it that switched its light on when it was bound in a certain way within the protein. They created chemical molecules based on the shape of this fluorophore and then developed an artificial RNA sequence, or "aptamer," that held the fluorophore in exactly the same way that GFP held its fluorophore. They named this RNA "Spinach" for its bright green fluorescence.

The researchers went even further. They also developed several other RNA-fluorophore pairs, in addition to Spinach, that each emit a different fluorescent color, just as GFP has been evolved to exhibit a palette of colors that helps researchers track many proteins at once. Whereas GFP derivatives are often named after fruits, the Weill Cornell researchers named their RNA mimics of GFP after vegetables -- Spinach, Carrot and Radish.

The Weill Cornell investigators have already begun to use Spinach to track non-coding RNAs in cells. "Our laboratory has been very interested understanding why defects in RNA trafficking and translocation lead to developmental disorders in children, such as mental retardation," says Dr. Jaffrey. Using Spinach, they were able to watch as a non-coding RNA, fluorescing green, rapidly clusters in response to cellular stress. "We expect that Spinach will provide new insights into RNA trafficking in cells, and how this is affected in medical disorders," he says.

"There is still a lot of mystery surrounding RNA in biology. Fluorescent labeling and imaging has proved to be a powerful tool for scientists in the past, and we are hoping that Spinach too will be a tool that helps accelerate scientific discovery," says Dr. Paige.

Dr. Karen Wu of the Department of Pharmacology is a co-author on the study.

The work was supported by the McKnight Neuroscience Technology Innovation Award and the National Institutes of Neurological Disorders and Stroke.

Email or share this story:

Wednesday, August 24, 2011

Increasing potency of HIV-battling proteins

ScienceDaily (July 28, 2011) — If one is good, two can sometimes be better. Researchers at the California Institute of Technology (Caltech) have certainly found this to be the case when it comes to a small HIV-fighting protein.See Also:Health & MedicineHIV and AIDSInfectious DiseasesSTDSexual HealthVirusesDiseases and ConditionsReferenceAntiviral drugTransmission (medicine)HIV testBlood test

The protein, called cyanovirin-N (CV-N), is produced by a type of blue-green algae and has gained attention for its ability to ward off several diseases caused by viruses, including HIV and influenza. Now Caltech researchers have found that a relatively simple engineering technique can boost the protein's battling prowess.

"By linking two cyanovirins, we were able to make significantly more potent HIV-fighting molecules," says Jennifer Keeffe, a staff scientist at Caltech and first author of a new paper describing the study in the Proceedings of the National Academy of Sciences (PNAS). "One of our linked molecules was 18 times more effective at preventing infection than the naturally occurring, single protein."

The team's linked pairs, or dimers, were able to neutralize all 33 subtypes of HIV that they were tested against. The researchers also found the most successful dimer to be similar or more potent than seven well-studied anti-HIV antibodies that are known to be broadly neutralizing.

CV-N binds well to certain carbohydrates, such as the kind found in high quantities connected to the proteins on the envelope that surrounds the HIV virus. Once attached, CV-N prevents a virus from infecting cells, although the mechanism by which it accomplishes this is not well understood.

What is known is that each CV-N protein has two binding sites where it can bind to a carbohydrate and that both sites are needed to neutralize HIV.

Once the Caltech researchers had linked two CV-Ns together, they wanted to know if the enhanced ability of their engineered dimers to ward off HIV was related to the availability of additional binding sites. So they engineered another version of the dimers -- this time with one or more of the binding sites knocked out -- and tested their ability to neutralize HIV.

It turns out that the dimers' infection-fighting potency increased with each additional binding site -- three sites are better than two, and four are better than three. The advantages seemed to stop at four sites, however; the researchers did not see additional improvements when they linked three or four CV-N molecules together to create molecules with six to eight binding sites.

Although CV-N has a naturally occurring dimeric form, it isn't stable at physiological temperatures, and thus mainly exists in single-copy form. To create dimers that would be stable under such conditions, the researchers covalently bound together two CV-N molecules in a head-to-tail fashion, using flexible polypeptide linkers of varying lengths.

Interestingly, by stabilizing the dimers and locking them into a particular configuration, it seems that the group created proteins with distances between binding sites that are very similar to those between the carbohydrate binding sites in a broadly neutralizing anti-HIV antibody.

"It is possible that we have created a dimer that has its carbohydrate binding sites optimally positioned to block infection," says Stephen Mayo, Bren Professor of Biology and Chemistry, chair of the Division of Biology, and corresponding author of the new paper.

Because it is active against multiple disease-causing viruses, including multiple strains of HIV, CV-N holds unique promise for development as a drug therapy. Other research groups have already started investigating its potential application in prophylactic gels and suppositories.

"Our hope is that those who are working to make prophylactic treatments using cyanovirin will see our results and will use CVN2L0 instead of naturally occurring cyanovirin," Keeffe says. "It has higher potency and may be more protective."

The work was funded by the National Security Science and Engineering Faculty Fellowship program, the Defense Advanced Research Projects Agency Protein Design Processes program, and the Bill and Melinda Gates Foundation through the Grand Challenges in Global Health Initiative.

Email or share this story:

Zinc lozenges may shorten common cold duration, Finnish research suggests

ScienceDaily (July 26, 2011) — Depending on the total dosage of zinc and the composition of lozenges, zinc lozenges may shorten the duration of common cold episodes by up to 40%, according to a study published in the Open Respiratory Medicine Journal.See Also:Health & MedicineDietary SupplementVitaminCold and FluInfectious DiseasesDiseases and ConditionsLiving WellReferenceCommon coldMicronutrientZincDietary mineral

For treating the common cold, zinc lozenges are dissolved slowly in the mouth. Interest in zinc lozenges started in the early 1980s from the serendipitous observation that a cold of a young girl with leukemia rapidly disappeared when she dissolved a therapeutic zinc tablet in her mouth instead of swallowing it. Since then over a dozen studies have been carried out to find out whether zinc lozenges are effective, but the results of those studies have diverged.

Dr. Harri Hemila of the University of Helsinki, Finland, carried out a meta-analysis of all the placebo-controlled trials that have examined the effect of zinc lozenges on natural common cold infections. Of the 13 trial comparisons identified, five used a total daily zinc dose of less than 75 mg and uniformly those five comparisons found no effect of zinc. Three trials used zinc acetate in daily doses of over 75 mg, with the average indicating a 42% reduction in the duration of colds. Five trials used zinc salts other than acetate in daily doses of over 75 mg, with the average indicating a 20% decrease in the duration of colds.

In several studies, zinc lozenges caused adverse effects, such as bad taste, but there is no evidence that zinc lozenges might cause long term harm. Furthermore, in the most recent trial on zinc acetate lozenges, there were no significant differences between the zinc and placebo groups in the occurrence of adverse effects although the daily dose of zinc was 92 mg. Dr. Hemila concluded that "since a large proportion of trial participants have remained without adverse effects, zinc lozenges might be useful for them as a treatment option for the common cold."

Email or share this story:

Modeling plant metabolism to optimize oil production

ScienceDaily (July 26, 2011) — Scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have developed a computational model for analyzing the metabolic processes in rapeseed plants -- particularly those related to the production of oils in their seeds. Their goal is to find ways to optimize the production of plant oils that have widespread potential as renewable resources for fuel and industrial chemicals.See Also:Plants & AnimalsSeedsEndangered PlantsMatter & EnergyOrganic ChemistryPetroleumEarth & ClimateEnergy and the EnvironmentOil SpillsReferenceCanolaAromatherapyBiomassLegume

The model, described in two featured articles in the August 1, 2011, issue of the Plant Journal, may help to identify ways to maximize the conversion of carbon to biomass to improve the production of plant-derived biofuels.

"To make efficient use of all that plants have to offer in terms of alternative energy, replacing petrochemicals in industrial processes, and even nutrition, it's essential that we understand their metabolic processes and the factors that influence their composition," said Brookhaven biologist Jorg Schwender, who led the development of the model with postdoctoral research associate Jordan Hay.

In the case of plant oils, the scientists' attention is focused on seeds, where oils are formed and accumulated during development. "This oil represents the most energy-dense form of biologically stored sunlight, and its production is controlled, in part, by the metabolic processes within developing seeds," Schwender said.

One way to study these metabolic pathways is to track the uptake and allotment of a form of carbon known as carbon-13 as it is incorporated into plant oil precursors and the oils themselves. But this method has limits in the analysis of large-scale metabolic networks such as those involved in apportioning nutrients under variable physiological conditions.

"It's like trying to assess traffic flow on roads in the United States by measuring traffic flow only on the major highways," Schwender said.

To address these more complex situations, the Brookhaven team constructed a computational model of a large-scale metabolic network of developing rapeseed (Brassica napus) embryos, based on information mined from biochemical literature, databases, and prior experimental results that set limits on certain variables. The model includes 572 biochemical reactions that play a role in the seed's central metabolism and/or seed oil production, and incorporates information on how those reactions are grouped together and interact.

The scientists first tested the validity of the model by comparing it to experimental results from carbon-tracing studies for a relatively simple reaction network -- the big-picture view of the metabolic pathways analogous to the traffic on U.S. highways. At that big-picture level, results from the two methods were largely consistent, providing validation for both the computer model and the experimental technique, while identifying a few exceptions that merit further exploration.

The scientists then used the model to simulate more complicated metabolic processes under varying conditions -- for example, changes in oil production or the formation of oil precursors in response to changes in available nutrients (such as different sources of carbon and nitrogen), light conditions, and other variables.

"This large-scale model is a much more realistic network, like a map that represents almost every street," Schwender said, "with computational simulations to predict what's going on." Continuing the traffic analogy, he said, "We can now try to simulate the effect of 'road blocks' or where to add new roads to most effectively eliminate traffic congestion."

The model also allows the researchers to assess the potential effects of genetic modifications (for example, inactivating particular genes that play a role in plant metabolism) in a simulated environment. These simulated "knock-out" experiments gave detailed insights into the potential function of alternative metabolic pathways -- for example, those leading to the formation of precursors to plant oils, and those related to how plants respond to different sources of nitrogen.

"The model has helped us construct a fairly comprehensive overview of the many possible alternative routes involved in oil formation in rapeseed, and categorize particular reactions and pathways according to the efficiency by which the organism converts sugars into oils. So at this stage, we can enumerate, better than before, which genes and reactions are necessary for oil formation, and which make oil production most effective," Schwender said.

The researchers emphasize that experimentation will still be essential to further elucidating the factors that can improve plant oil production. "Any kind of model is a largely simplified representation of processes that occur in a living plant," Schwender said. "But it provides a way to rapidly assess the relative importance of multiple variables and further refine experimental studies. In fact, we see our model and experimental methods such as carbon tracing as complementary ways to improve our understanding of plants' metabolic pathways."

The scientists are already incorporating information from this study that will further refine the model to increase its predictive power, as well as ways to extend and adapt it for use in studying other plant systems.

This work was supported by the DOE Office of Science.

Email or share this story:

Tuesday, August 23, 2011

Brain autopsies of four former football players reveal not all get chronic traumatic encephalopathy

ScienceDaily (July 26, 2011) — Preliminary results from the first four brains donated to the Canadian Sports Concussion Project at the Krembil Neuroscience Centre, TorontoWesternHospital, reveal that two of the four former Canadian Football League (CFL) players suffered from a brain disease known as Chronic Traumatic Encephalopathy (CTE), while two did not show signs of CTE.See Also:Health & MedicineChronic IllnessHealthy AgingDiseases and ConditionsMind & BrainBrain InjuryDisorders and SyndromesIntelligenceReferenceDementia with Lewy bodiesDementiaHead injuryNeurology

Bobby Kuntz, a former Toronto Argonaut and Hamilton Tiger-Cat and Jay Roberts, an Ottawa Roughrider both had a history of repeated concussions during their careers and showed the characteristic signs of CTE, an abnormal build-up of a protein called Tau in the brain, and other degenerative changes.

CTE can result in memory impairment, emotional instability, erratic behavior, depression, and problems with impulse control. CTE may eventually progress to full-blown dementia. Dr. Hazrati is very clear, however, to emphasize that the precise relationship between concussions and neurodegeneration remains to be demonstrated by future research.

Peter Ribbins, a former Winnipeg Blue Bomber, passed away in December 2010, at age 63 of Parkinson's disease. Autopsy results show he did not have signs of CTE. Tony Proudfoot, anall-star defensive back for the Montreal Alouettes, died at age 61 in 2011 of Lou Gehrig's disease (a neurodegenerative condition also known as ALS). Although a connection between ALS and repeated head trauma is being researched, Proudfoot did not have signs of CTE. Both of these players were in the league at a time when it was common to spear tackle with the crown of the head. According to the Canadian Football League Alumni Association (CFLAA), Proudfoot experienced repeated head trauma as a hard-hitting defensive back throughout his 12 seasons in the league.

Kuntz passed away in February 2011 at age 79 after a long battle with Parkinson's Disease and diffuse Lewy body disease, a condition that overlaps with Parkinson's and Alzheimer's. Roberts, 67, who died in October 2010, suffered from dementia and lung cancer. The autopsies were performed by Dr. Lili-Naz Hazrati, a neuropathologist in the Laboratory Medicine Program at the University Health Network.

"While both of these men appeared to have pathological signs of CTE, they also suffered from other serious neurological and vascular related diseases," said Dr. Hazrati. "Right now we have more questions than answers about the relationship between repeated concussions and late brain degeneration. For example, we are still trying to understand why these two players acquired CTE and the other two did not."

Mary Kuntz, wife of the late Bobby Kuntz, donated his brain to the Canadian Sports Concussion Project at the Krembil Neuroscience Centre and believes the more players who donate their brains, the better the chances of helping future athletes.

"We've always had questions about Bob's health, because there were so many conflicting medical opinions," said Mary Kuntz. "We knew there must have been some effect from all of the concussions over the years, and this was an affirmation that concussions did have a part in his health problems.

"Young players should know the risks of concussions. When you are young, you can't believe what can happen to you when you are older, but we have lived though it. What is good about this study is that there will be more evidence and information for players."

"We were very happy to be involved in this and it has brought us a sense of closure."

The Canadian Sports Concussion Project at the Krembil Neuroscience Centre is organized by a team of concussion experts including Dr. Charles Tator and Dr. Richard Wennberg and scientists from several other Canadian institutions. The focus of the project is to further our understanding of how concussions affect the brain.

"There are still so many unanswered questions surrounding concussion and the long-term consequences of repeated head injuries," said Dr. Tator. "We are trying to determine why some athletes in contact sports develop CTE and others don't, as well as how many concussions lead to the onset of this degenerative brain disease. Also, we need to develop tests to detect this condition at an early stage and to discover treatments."

According to Jed Roberts, son of Jay Roberts, he and his sisters began noticing early signs of their father's memory decline when he starting repeating stories, but insisting he had never told them. "My dad had numerous concussions, although they were undocumented, and I think he knew there was something was wrong, which is why he wanted to help find answers that would hopefully protect future football players," said Jed, a former CFL player with the Edmonton Eskimos. "I think it is really important that we create awareness around this issue, so that players can live healthy, productive lives beyond the game."

Leo Ezerins, former CFL player and current Executive Director of the CFLAA is a member of the Project Team. It has been through the joint efforts of the CFLAA and the research team that these four donations were made possible.

Email or share this story:

Scientists developing new therapy for HER2-positive breast cancer

ScienceDaily (July 26, 2011) — Patients with HER2-positive breast cancer may have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research, a journal of the American Association for Cancer Research.See Also:Health & MedicineBreast CancerCancerBrain TumorLung CancerOvarian CancerSkin CancerReferenceBreast cancerMonoclonal antibody therapyMetastasisNanomedicine

Jacek Capala, Ph.D., D.Sc., an investigator at the National Cancer Institute, and colleagues designed, produced and tested HER2-Affitoxin, a novel protein that combines HER2-specific affibody molecules and a modified bacterial toxin, PE38.

"Unlike the current HER2-targeted therapeutics, such as Herceptin, this protein does not interfere with the HER2 signaling pathway but, instead, uses HER2 as a target to deliver a modified form of bacterial toxin specifically to the HER2-positive cancer cells. When cells absorb the toxin, it interferes with protein production and, thereby, kills them," said Capala.

At least, that is what happened in Capala's laboratory. After Affitoxin was injected into tumor-bearing mice, even relatively large, aggressive tumors stopped growing and most of them disappeared. The effect was strong enough that Capala believes it warrants a clinical trial.

"Herceptin has revolutionized the treatment of patients with HER2-positive breast cancer, but a significant number of tumors acquire resistance to the drug," said Capala. "Affitoxin could offer another therapeutic option for those patients whose tumors no longer respond to Herceptin."

Email or share this story:

Medicare Part D associated with reduction in nondrug medical spending

ScienceDaily (July 26, 2011) — Among elderly Medicare beneficiaries with limited prior drug coverage, implementation of Medicare Part D was associated with significant reductions in nondrug medical spending, such as for inpatient and skilled nursing facility care, according to a study in the July 27 issue of JAMA.See Also:Health & MedicinePharmacologyToday's HealthcareHealth PolicyPersonalized MedicineHIV and AIDSControlled SubstancesReferencePalliative carePharmaceutical companyDetoxClinical trial

"Implementation of the Medicare prescription drug benefit (Part D) in January 2006 was followed by increased medication use, reduced out-of-pocket costs, and improved adherence to essential medications for elderly persons. The effects of Part D on nondrug medical spending for Medicare beneficiaries have not been clearly defined," according to background information in the article.

J. Michael McWilliams, M.D., Ph.D., of Harvard Medical School and Brigham and Women's Hospital, Boston, and colleagues compared nondrug medical spending for traditional Medicare beneficiaries before and after the implementation of Part D. Nationally representative survey data and linked Medicare claims from 2004-2007 were used to compare nondrug medical spending before and after the implementation of Part D by self-reported generosity of prescription drug coverage (extent to which medications were mostly or completely covered) before 2006. Participants included 6,001 elderly Medicare beneficiaries from the Health and Retirement Study, including 2,538 with generous and 3,463 with limited drug coverage before 2006.

Adjusted total nondrug medical spending before implementation of Part D was consistently but not significantly higher for participants with limited drug coverage than for participants with generous drug coverage (7.6 percent relative difference). The researchers found that nondrug medical spending after Part D implementation was 3.9 percent lower for participants with limited prior drug coverage than for those with generous prior drug coverage, which was a significant differential